Evidence map›Paper›PMID 39256511›Full record

ArticleScientific reports2024

NACC2, a molecular effector of miR-132 regulation at the interface between adult neurogenesis and Alzheimer's disease.

Amber Penning, Sarah Snoeck, Oxana Garritsen, Giorgia Tosoni, Amber Hof, Fleur de Boer, Joëlle van Hasenbroek, Lin Zhang, Nicky Thrupp, Katleen Craessaerts and 2 more

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Amber Penning *Netherlands Institute for Neuroscience, Amsterdam, The Netherlands.
Sarah Snoeck *Netherlands Institute for Neuroscience, Amsterdam, The Netherlands.
Oxana GarritsenUMC Utrecht Brain Center, Utrecht University, Utrecht, The Netherlands.
Giorgia TosoniNetherlands Institute for Neuroscience, Amsterdam, The Netherlands.
Amber HofNetherlands Institute for Neuroscience, Amsterdam, The Netherlands.
Fleur de BoerNetherlands Institute for Neuroscience, Amsterdam, The Netherlands.
Joëlle van HasenbroekNetherlands Institute for Neuroscience, Amsterdam, The Netherlands.
Lin ZhangNetherlands Institute for Neuroscience, Amsterdam, The Netherlands.
Nicky ThruppVIB-KU Leuven Center for Brain & Disease Research, Leuven, Belgium.
Katleen CraessaertsVIB-KU Leuven Center for Brain & Disease Research, Leuven, Belgium.
Mark FiersVIB-KU Leuven Center for Brain & Disease Research, Leuven, Belgium.
Evgenia SaltaNetherlands Institute for Neuroscience, Amsterdam, The Netherlands. e.salta@nin.knaw.nl.

Funding

Alzheimer Nederland WE.03-2020-04Health~Holland LSHM20095
6 · The paper itself

Abstract

The generation of new neurons at the hippocampal neurogenic niche, known as adult hippocampal neurogenesis (AHN), and its impairment, have been implicated in Alzheimer's disease (AD). MicroRNA-132 (miR-132), the most consistently downregulated microRNA (miRNA) in AD, was recently identified as a potent regulator of AHN, exerting multilayered proneurogenic effects in adult neural stem cells (NSCs) and their progeny. Supplementing miR-132 in AD mouse brain restores AHN and relevant memory deficits, yet the exact mechanisms involved are still unknown. Here, we identify NACC2 as a novel miR-132 target implicated in both AHN and AD. miR-132 deficiency in mouse hippocampus induces Nacc2 expression and inflammatory signaling in adult NSCs. We show that miR-132-dependent regulation of NACC2 is involved in the initial stages of human NSC differentiation towards astrocytes and neurons. Later, NACC2 function in astrocytic maturation becomes uncoupled from miR-132. We demonstrate that NACC2 is present in reactive astrocytes surrounding amyloid plaques in mouse and human AD hippocampus, and that there is an anticorrelation between miR-132 and NACC2 levels in AD and upon induction of inflammation. Unraveling the molecular mechanisms by which miR-132 regulates neurogenesis and cellular reactivity in AD, will provide valuable insights towards its possible application as a therapeutic target.

Indexed as

Alzheimer DiseaseAstrocytesHippocampusMicroRNAsNeural Stem CellsNeurogenesisAnimalsCell DifferentiationGene Expression RegulationHumansMiceNeuronsMicroRNAsMIRN132 microRNA, humanMIRN132 microRNA, mouse

Identifiers

PMID39256511
PMCPMC11387632

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.